| Host |
Rabbit |
| Klon |
DBRRM2.85 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human CEA protein fragment |
| Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB118R-01 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM2.85 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human CEA protein fragment |
| Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB118R-05 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM2.85 |
| Format |
ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
--- |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human CEA protein fragment |
| Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD118R |
-
|
| Host |
Rabbit |
| Klon |
ZR370 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant full-length human CEA protein |
| Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
1 ml |
Concentrate |
CE/IVD |
Z2661RL |
-
|
| Host |
Rabbit |
| Klon |
ZR370 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant full-length human CEA protein |
| Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
7 ml |
ready-to-use |
CE/IVD |
Z2661RP |
-
|
| Host |
Rabbit |
| Klon |
ZR370 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant full-length human CEA protein |
| Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
0.5 ml |
Concentrate |
CE/IVD |
Z2661RS |
-
|
| Host |
Rabbit |
| Klon |
ZR370 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant full-length human CEA protein |
| Lokalisation |
Cytoplasmic and luminal membrane |
CEACAM5
|
Zeta Corporation |
ZR370 |
0.1 ml |
Concentrate |
CE/IVD |
Z2661RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Small Intestine |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide sulfated cholecystokinin (26-33) amide (sulfated CCK-8). |
| Lokalisation |
Cytoplasmic, Lumenal Membrane |
Cholecystokinin (26-33)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-4514 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
EL, IP |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Purified Choleragenoid |
Cholera Toxin (beta Subunit)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
603-1886 |
-
|
| Host |
Mouse |
| Klon |
LK2H10+PHE5 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Pancreas, Adrenal gland |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+ Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Biocare Medical |
LK2H10+PHE5 |
6 ml |
Ready-to-use |
CE/IVD |
AVI010G |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP008 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP008-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Pancreas |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP008-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM12 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or neuroendocrine tumor. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Chromogranin A protein |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
1 ml |
Concentrate |
CE/IVD |
Z2347ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM12 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or neuroendocrine tumor. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Chromogranin A protein |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2347MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM12 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or neuroendocrine tumor. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Chromogranin A protein |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2347MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM12 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Pancreas or neuroendocrine tumor. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human Chromogranin A protein |
| Lokalisation |
Cytoplasm |
Chromogranin A
|
Zeta Corporation |
ZM12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2347MT |
-
|
| Host |
Mouse |
| Klon |
4E1 |
| Format |
Purified |
| Methode |
F, P, WB, EL |
| Isotyp |
Mouse IgG3 |
| Verdünnung |
Native pancreatic |
Chymotrypsin
|
Zytomed Systems GmbH |
4E1 |
200 µg |
Purified |
RUO |
603-1908 |
-
|
| Host |
Mouse+Rabbit |
| Klon |
34ßE12+4A4+13H4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 or pH 6.2 |
| Positivkontrolle |
Prostate intraepithelial neoplasia PIN |
| Verdünnung |
- |
| Isotyp |
MouseIgG1/kappa+IgG2a+RabbitIgG |
| Lokalisation |
Cytoplasmic and nuclear |
CK HMW + p63 + AMACR (RM)
|
Biocare Medical |
34ßE12+4A4+13H4 |
6 ml |
Ready-to-use |
CE/IVD |
API3154DSAA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
34ßE12+4A4+13H4 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified Citrate pH 6.0 or pH 6.2 |
| Positivkontrolle |
Prostate intraepithelial neoplasia PIN |
| Verdünnung |
- |
| Isotyp |
MouseIgG1/kappa+IgG2a+RabbitIgG |
| Lokalisation |
Cytoplasmic and nuclear |
CK HMW + p63 + AMACR (RM)
|
Biocare Medical |
34ßE12+4A4+13H4 |
25 ml |
Ready-to-use |
CE/IVD |
API3154DSH |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Skin, Breast Carcinoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human Claudin-1. |
| Lokalisation |
Cell Membrane on Skin, Cytoplasmic/Nuclear on Mamma |
Claudin 1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-3414 |
-
|
| Host |
Rabbit |
| Klon |
SP128 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Liver, hepatocellular carcinoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
| Lokalisation |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
0.1 ml |
Concentrate |
RUO |
503-4280 |
-
|
| Host |
Rabbit |
| Klon |
SP128 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Liver, liver carcinoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
| Lokalisation |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
0.5 ml |
Concentrate |
RUO |
503-4282 |
-
|
| Host |
Rabbit |
| Klon |
SP128 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Liver, liver carcinoma |
| Verdünnung |
1:200 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human claudin-1 protein |
| Lokalisation |
Cell Membrane |
Claudin 1
|
Zytomed Systems GmbH |
SP128 |
1 ml |
Concentrate |
RUO |
503-4284 |
-
|
| Host |
Mouse |
| Klon |
3E2C1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma or breast carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
| Lokalisation |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3121A |
-
|
| Host |
Mouse |
| Klon |
3E2C1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma or breast carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
| Lokalisation |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3121B |
-
|
| Host |
Mouse |
| Klon |
3E2C1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon carcinoma or breast carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide corresponding to a 22 amino acid sequence derived from the C-terminal region of human Claudin-4 |
| Lokalisation |
Cell membrane |
Claudin 4
|
Biocare Medical |
3E2C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3121AA |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.82 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50-1:100 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB116R |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.82 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50-1:100 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
0.1 ml |
Concentrate |
Übergangsfrist |
RMAB116R-01 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.82 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Stomach |
| Verdünnung |
1:50-1:100 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
0.5 ml |
Concentrate |
Übergangsfrist |
RMAB116R-05 |
-
|
| Host |
Rabbit |
| Klon |
DBRRM1.82 |
| Format |
ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Stomach |
| Verdünnung |
--- |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human Claudin18.2protein fragment (around aa 1-100) |
| Lokalisation |
Cell membrane |
Claudin 18.2
|
Diagnostic Biosystems |
DBRRM1.82 |
6 ml |
ready-to-use |
Übergangsfrist |
RMPD116R |
-
|
| Host |
Rabbit |
| Klon |
ZR451 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Carcinomas |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Lokalisation |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
1 ml |
Concentrate |
RUO |
Z2807RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR451 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Carcinomas |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Lokalisation |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
7 ml |
Ready-to-use |
RUO |
Z2807RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR451 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Carcinomas |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Lokalisation |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
0.5 ml |
Concentrate |
RUO |
Z2807RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR451 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Carcinomas |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa1-100) of human Claudin18.2 protein |
| Lokalisation |
Membrane |
Claudin 18.2
|
Zeta Corporation |
ZR451 |
0.1 ml |
Concentrate |
RUO |
Z2807RT-R |
-
|
| Host |
Rabbit |
| Klon |
ZR456 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
CMV infected tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant CMV-p65 protein |
| Lokalisation |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
1 ml |
Concentrate |
RUO |
Z2818RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR456 |
| Format |
RTU |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
CMV infected tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant CMV-p65 protein |
| Lokalisation |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
7 ml |
RTU |
RUO |
Z2818RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR456 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
CMV infected tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant CMV-p65 protein |
| Lokalisation |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
0.5 ml |
Concentrate |
RUO |
Z2818RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR456 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
CMV infected tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant CMV-p65 protein |
| Lokalisation |
Nucleus/cytoplasmic |
CMV
|
Zeta Corporation |
ZR456 |
0.1 ml |
Concentrate |
RUO |
Z2818RT-R |
-
|
| Host |
Mouse |
| Klon |
9E10 |
| Format |
Purified |
| Methode |
F, P, EL, WB |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide sequence AEEQKLISEEDLL corresponding to the C-terminal region of human c-myc |
cMyc
|
Zytomed Systems GmbH |
9E10 |
1 mg |
Purified |
RUO |
603-1940 |
-
|
| Host |
Mouse |
| Klon |
9E10 |
| Format |
Purified |
| Methode |
F, P, EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Synthetic peptide sequence AEEQKLISEEDLL corresponding to the C-terminal region of human c-myc |
cMyc
|
Zytomed Systems GmbH |
9E10 |
100 µg |
Purified |
RUO |
603-1941 |
-
|
| Host |
Rabbit |
| Klon |
EP121 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
ER2 |
| Positivkontrolle |
Some prostate or breast cancers |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in N-terminus of human c-Myc |
| Lokalisation |
Nucleus |
cMyc
|
Biocare Medical |
EP121 |
7 ml |
Ready-to-use |
CE/IVD |
ALI415G7 |
-
|
| Host |
Rabbit |
| Klon |
EP121 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Some prostate or breast cancers |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in N-terminus of human c-Myc |
| Lokalisation |
Nucleus |
cMyc
|
Biocare Medical |
EP121 |
0.1 ml |
Concentrate |
CE/IVD |
CME415AK |
-
|
| Host |
Mouse |
| Klon |
9E10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast carcinoma, colon adenocarcinoma |
| Verdünnung |
1:50 - 1 :100 |
| Isotyp |
IgG 1 kappa |
| Verdünnung |
f human c-Myc |
| Lokalisation |
Nucleus |
cMyc
|
Diagnostic Biosystems |
9E10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM211 |
-
|
| Host |
Mouse |
| Klon |
9E10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast carcinoma, colona adenocarcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Verdünnung |
f human c-Myc |
| Lokalisation |
Nucleus |
cMyc
|
Diagnostic Biosystems |
9E10 |
25 ml |
Ready-to-use |
CE/IVD |
PDM211-25 |
-
|
| Host |
Rabbit |
| Klon |
EP121 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Some prostate or breast cancers |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in N-terminus of human c-Myc |
| Lokalisation |
Nucleus |
cMyc
|
Biocare Medical |
EP121 |
6 ml |
Ready-to-use |
CE/IVD |
PME415AA |
-
|
| Host |
Mouse |
| Klon |
NFI/20 |
| Format |
Lyophilised |
| Methode |
F, EL, WB |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human collagen type I |
Collagen I
|
Zytomed Systems GmbH |
NFI/20 |
100 µg |
Lyophilised |
RUO |
603-1954 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised (for 0.5 ml) |
| Methode |
F, P, EL |
| Vorbehandlung |
Pepsin |
| Verdünnung |
1:10 - 1:50 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Collagen type I from human placenta |
Collagen I
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Lyophilised (for 0.5 ml) |
RUO |
603-1955 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
F, P, IF, EL, WB |
| Verdünnung |
1:250 - 1:1000 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Native type I collagen from mouse skin |
Collagen I
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Purified |
RUO |
603-1958 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
F, EL |
| Verdünnung |
1:10 - 1:50 (P) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Human Collagen type II from cartilage |
Collagen II
|
Zytomed Systems GmbH |
polyclonal |
500 µl |
Lyophilised |
RUO |
603-1970 |
-
|